D03.3
Melanoma in situ of other and unspecified parts of face
Clinical Classification Guidelines
Medical Intelligence & Overview
Melanoma in situ of other and unspecified parts of the face refers to an early stage skin cancer that is confined to the top layer of the skin in areas of the face that are not specifically categorized as common sites for melanoma, such as the nose or cheeks. This condition is characterized by the abnormal growth of melanocytes, the cells responsible for pigment in the skin, which have not yet invaded deeper layers. Recognized as a critical phase in skin cancer development, melanoma in situ presents an opportunity for early intervention and effective treatment.
Causes & Symptoms
Clinical Causes: Excessive exposure to ultraviolet (UV) radiation from sunlight or tanning beds Genetic predisposition, including family history of melanoma Fair skin, especially with a tendency to burn easily Presence of numerous or atypical moles History of sunburns, particularly during childhood Occupation or lifestyle factors increasing UV exposure
Key Symptoms: Flat, irregularly shaped, pigmented lesion on the face Lesions with uneven borders and multiple colors (shades of brown, black, or tan) Changes in size, shape, or color of a skin spot Lesion that slowly enlarges over time Lesions that may become raised or develop a scaly surface Asymmetry in the lesion's shape or color distribution
Diagnostic & Treatment
Diagnosis Path: Dermatoscopy: A specialized skin examination technique to evaluate lesion structures Biopsy: Removing a small sample of the lesion for microscopic examination to confirm melanoma in situ Histopathological analysis: Laboratory examination to assess cellular arrangements and identify malignant characteristics Additional imaging tests may be considered if there is concern about lesion spread or involvement
Treatment Protocols: Surgical excision: Complete removal of the lesion with clear margins, often performed under local anesthesia Mohs micrographic surgery: A tissue-sparing technique offering precise removal while conserving healthy tissue, especially useful for facial areas Topical therapies: Such as imiquimod or topical interferon for select cases, though surgical removal is typically preferred Photodynamic therapy: A light-based treatment occasionally used for superficial lesions Follow-up care: Regular skin examinations to monitor for new or recurring lesions
Clinical Advice & FAQs
Billing Guidance
Is D03.3 a billable ICD-10 code?
Yes, D03.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D03.3?
Clinical documentation must specify the nature of Melanoma in situ of other and unspecified parts of face and any associated comorbidities for accurate reporting.
Cite this Clinical Reference